Gheuens Sarah sold $75K of AGIO

Gheuens Sarah (Chief Medical Officer) sold 1,989 shares of AGIOS PHARMACEUTICALS, INC. (AGIO) at an average of $37.53 ($37.52–$37.53) across 2 trades over 2026-10-21 to 2026-10-22 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Gheuens Sarah
Published Oct 23, 2026, 8:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 23, 2026, 8:08 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$AGIO
Neutral
high confidence
Mentioned
$AGIO
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$AGIONeutralLow
01

Why it matters

A modest insider sell typically has limited price effect unless accompanied by other news.

02

Market read

The filing provides a fresh data point for traders monitoring insider activity, but the small size limits trading significance.

03

What to watch

Potential upcoming clinical data releases that may offset any negative sentiment from the sale.

Relevance 2/10Novelty 2/10Timing: post‑market filing today

Background

Form 4 filings disclose insider transactions; investors watch for material changes in insider holdings.

Company-level read

Ticker impact

$AGIONeutralHigh confidence
Context

Chief Medical Officer sold 1,989 shares (~$75K) via a 10b5‑1 plan, reducing her stake to 54,645 shares.

Expected impact

likely slight pressure as the market prices in the insider sell.

Evidence & confidence

Form 4 filing is a primary source; the transaction size is under $1M, typical for routine insider sales, so impact is limited.

Market effects

Minimal effect on biotech sector; similar insider sales are common.

No regional impact.

Limited to AGIO shareholders.

Counterpoint

The sale could be purely portfolio rebalancing and not indicative of company fundamentals.

Key entities

  • Agios Pharmaceuticals, Inc.

    Biotech firm developing therapies for rare genetic diseases.

  • Gheuens Sarah

    Chief Medical Officer of Agios, reporting the sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$AGIOMed

Agios Earnings Call: AQVESME Growth Meets FDA Uncertainty

Agios Pharmaceuticals (AGIO) reported Q3 revenue of $55.4M, up from $12.9M a year earlier, driven by strong AQVESME adoption. The company saw 177 new prescriptions, with 75% patient persistence. International revenue rose 74% to $6.6M. Agios prepares for a potential sickle cell launch, but faces FDA review extension and higher expenses. Q3 net loss narrowed to $65M from $103M YoY.

$AGIOMed

Agios Pharmaceuticals Inc (AGIO) (Q3 2026) Earnings Call Highlights: Revenue Surges 4x

Agios Pharmaceuticals (AGIO) reported Q3 2026 revenue surged 4x, but faced a 3-month FDA review delay for mitapivat in sickle cell disease, increasing uncertainty. Net loss narrowed to $65M from $103.4M YoY. Selling expenses rose to $56.5M, and no 2027 guidance was provided. Thalassemia launch growth may moderate, with 177 prescriptions as a new run rate. Pipeline programs remain early-stage.

$AGIOMed

Agios Pharmaceuticals, Inc. Q3 2026 Earnings Call Summary

Agios Pharmaceuticals reported Q3 2026 revenue of $55.4M, driven by mitapivat in thalassemia. The company plans to cut R&D headcount by 35% to focus on rare hematology and aims for non-GAAP profitability in 2028. Mitapivat's sickle cell disease approval was delayed to February 2027 due to FDA review. The company is also advancing AG-236 for polycythemia vera and cevidoplenib for immune thrombocytopenia.

$AGIOMed

Agios (AGIO) Q3 2026 Earnings Call Transcript

Agios (AGIO) reported Q3 2026 earnings, highlighting $55.4M in mitapivat revenue, a 3-month FDA review extension for sickle cell disease, and $907M in cash. The company plans to reduce R&D headcount by 35% and aims for non-GAAP profitability in 2028. Mitapivat saw a 4x revenue increase YoY, with strong U.S. and international demand.

$AGIOHigh

Truist cuts Agios Pharma stock price target on SCD concerns

Truist Securities reduced its price target for Agios Pharmaceuticals (NASDAQ: AGIO) to $35 from $37, citing concerns about sickle cell disease. The stock is currently trading at $28.38, down 15.7% over the past week. Agios reported Q3 2026 earnings that missed expectations, but revenue exceeded estimates. The company announced a 35% reduction in R&D headcount, aiming for non-GAAP profitability in 2028.

$AGIOHigh

Agios Q3 Mitapivat Revenue Surges More Than Fourfold; Sickle Cell FDA Decision Set For February 2027

Agios Pharmaceuticals (AGIO) reported Q3 2026 revenue of $55.4M for mitapivat products, up over fourfold YoY. U.S. revenue rose to $48.7M, while ex-U.S. revenue increased to $6.6M. Net loss narrowed to $65.0M. The FDA extended the PDUFA goal date for mitapivat in sickle cell disease to February 2027. Agios plans to reduce R&D workforce by over 35% by year-end 2026.